These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 21765407)

  • 1. Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel.
    Liu F; Park JE; Qian WJ; Lim D; Gräber M; Berg T; Yaffe MB; Lee KS; Burke TR
    Nat Chem Biol; 2011 Jul; 7(9):595-601. PubMed ID: 21765407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mono-anionic phosphopeptides produced by unexpected histidine alkylation exhibit high Plk1 polo-box domain-binding affinities and enhanced antiproliferative effects in HeLa cells.
    Qian WJ; Park JE; Lim D; Lai CC; Kelley JA; Park SY; Lee KW; Yaffe MB; Lee KS; Burke TR
    Biopolymers; 2014 Nov; 102(6):444-55. PubMed ID: 25283071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Highly Selective 1,2,3-Triazole-containing Peptidic Polo-like Kinase 1 Polo-box Domain-binding Inhibitors.
    Zhao XZ; Tsuji K; Hymel D; Burke TR
    Molecules; 2019 Apr; 24(8):. PubMed ID: 31014020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1.
    Yun SM; Moulaei T; Lim D; Bang JK; Park JE; Shenoy SR; Liu F; Kang YH; Liao C; Soung NK; Lee S; Yoon DY; Lim Y; Lee DH; Otaka A; Appella E; McMahon JB; Nicklaus MC; Burke TR; Yaffe MB; Wlodawer A; Lee KS
    Nat Struct Mol Biol; 2009 Aug; 16(8):876-82. PubMed ID: 19597481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of a cell-permeable, drug-like small molecule inhibitor targeting the polo-box domain of polo-like kinase 1.
    Srinivasrao G; Park JE; Kim S; Ahn M; Cheong C; Nam KY; Gunasekaran P; Hwang E; Kim NH; Shin SY; Lee KS; Ryu E; Bang JK
    PLoS One; 2014; 9(9):e107432. PubMed ID: 25211362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced cellular uptake of a TAT-conjugated peptide inhibitor targeting the polo-box domain of polo-like kinase 1.
    Kim SM; Chae MK; Lee C; Yim MS; Bang JK; Ryu EK
    Amino Acids; 2014 Nov; 46(11):2595-603. PubMed ID: 25151148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide-based inhibitors of Plk1 polo-box domain containing mono-anionic phosphothreonine esters and their pivaloyloxymethyl prodrugs.
    Qian WJ; Park JE; Lim D; Park SY; Lee KW; Yaffe MB; Lee KS; Burke TR
    Chem Biol; 2013 Oct; 20(10):1255-64. PubMed ID: 24120332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain.
    Chen Y; Zhang J; Li D; Jiang J; Wang Y; Si S
    Oncotarget; 2017 Jan; 8(1):1234-1246. PubMed ID: 27902479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and evaluation of d-amino acid-containing peptidomimetics targeting the polo-box domain of polo-like kinase 1.
    Li Z; Zhang Z; Chen Y; Tang S; Lin T; Huang J; Li B; Jiang C
    Bioorg Chem; 2019 Apr; 85():534-540. PubMed ID: 30807896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-proteinogenic amino acids in the pThr-2 position of a pentamer peptide that confer high binding affinity for the polo box domain (PBD) of polo-like kinase 1 (Plk1).
    Qian WJ; Park JE; Lee KS; Burke TR
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7306-8. PubMed ID: 23159568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of unanticipated alkylation at the N(π) position of a histidyl residue under Mitsunobu conditions and synthesis of orthogonally protected histidine analogues.
    Qian W; Liu F; Burke TR
    J Org Chem; 2011 Nov; 76(21):8885-90. PubMed ID: 21950469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype.
    McInnes C; Estes K; Baxter M; Yang Z; Farag DB; Johnston P; Lazo JS; Wang J; Wyatt MD
    Mol Cancer Ther; 2012 Aug; 11(8):1683-92. PubMed ID: 22848093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides.
    Zhao XZ; Hymel D; Burke TR
    Bioorg Med Chem; 2017 Oct; 25(19):5041-5049. PubMed ID: 28285924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of the Allosteric Communication between the Polo-Box Domain and the Catalytic Domain in Plk1 by Small Compounds.
    Raab M; Sanhaji M; Pietsch L; Béquignon I; Herbrand AK; Süß E; Gande SL; Caspar B; Kudlinzki D; Saxena K; Sreeramulu S; Schwalbe H; Strebhardt K; Biondi RM
    ACS Chem Biol; 2018 Aug; 13(8):1921-1931. PubMed ID: 29927572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of high affinity polo-like kinase 1 (Plk1) polo-box domain binding peptides using oxime-based diversification.
    Liu F; Park JE; Qian WJ; Lim D; Scharow A; Berg T; Yaffe MB; Lee KS; Burke TR
    ACS Chem Biol; 2012 May; 7(5):805-10. PubMed ID: 22292814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphatase-Stable Phosphoamino Acid Mimetics That Enhance Binding Affinities with the Polo-Box Domain of Polo-like Kinase 1.
    Hymel D; Burke TR
    ChemMedChem; 2017 Feb; 12(3):202-206. PubMed ID: 27992122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo.
    Yuan J; Sanhaji M; Krämer A; Reindl W; Hofmann M; Kreis NN; Zimmer B; Berg T; Strebhardt K
    Am J Pathol; 2011 Oct; 179(4):2091-9. PubMed ID: 21839059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new class of peptidomimetics targeting the polo-box domain of Polo-like kinase 1.
    Ahn M; Han YH; Park JE; Kim S; Lee WC; Lee SJ; Gunasekaran P; Cheong C; Shin SY; Kim HY; Ryu EK; Murugan RN; Kim NH; Bang JK
    J Med Chem; 2015 Jan; 58(1):294-304. PubMed ID: 25347203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Macrocyclic Peptidomimetics Targeting the Polo-Box Domain of Polo-Like Kinase 1.
    Ryu S; Park JE; Ham YJ; Lim DC; Kwiatkowski NP; Kim DH; Bhunia D; Kim ND; Yaffe MB; Son W; Kim N; Choi TI; Swain P; Kim CH; Lee JY; Gray NS; Lee KS; Sim T
    J Med Chem; 2022 Feb; 65(3):1915-1932. PubMed ID: 35029981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histidine N(τ)-cyclized macrocycles as a new genre of polo-like kinase 1 polo-box domain-binding inhibitors.
    Hymel D; Grant RA; Tsuji K; Yaffe MB; Burke TR
    Bioorg Med Chem Lett; 2018 Oct; 28(19):3202-3205. PubMed ID: 30174151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.